Literature DB >> 27442517

Notes from the Field: Rickettsia parkeri Rickettsiosis - Georgia, 2012-2014.

Anne Straily, Amanda Feldpausch, Carl Ulbrich, Kiersten Schell, Shannon Casillas, Sherif R Zaki, Amy M Denison, Marah Condit, Julie Gabel, Christopher D Paddock.   

Abstract

During 2012-2014, five cases of Rickettsia parkeri rickettsiosis were identified by a single urgent care practice in Georgia, located approximately 40 miles southwest of Atlanta. Symptom onset occurred during June-October, and all patients had a known tick bite. Patients ranged in age from 27 to 72 years (median = 53 years), and all were male. The most commonly reported initial signs were erythema (n = 3) and swelling (n = 2) at the site of the bite. Two patients reported fever and a third patient reported a rash and lymphadenopathy without fever. Other symptoms included myalgia (n = 3), chills (n = 3), fatigue (n = 2), arthralgia (n = 2), and headache (n = 2). Eschar biopsy specimens were collected from each patient using a 4-mm or 5-mm punch and placed in 10% neutral buffered formalin or sterile saline. These specimens were tested by immunohistochemical (IHC) stains, quantitative polymerase chain reaction (qPCR) assays, or cell culture isolation to determine if there was evidence of infection with a Rickettsia species (1). IHC evidence of spotted fever group rickettsiae was found in the eschar biopsy specimens in all five cases. In four cases, the biopsy specimens were also positive for R. parkeri by qPCR. The fifth case (specimen positive only by IHC testing) was considered a probable R. parkeri case based on clinical signs and symptoms. R. parkeri was grown in cell culture from one specimen from which isolation was attempted. All patients were treated with oral doxycycline (100 mg twice daily) for a minimum of 10 days, and all recovered.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27442517     DOI: 10.15585/mmwr.mm6528a3

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  7 in total

1.  Unique Strain of Rickettsia parkeri Associated with the Hard Tick Dermacentor parumapertus Neumann in the Western United States.

Authors:  Christopher D Paddock; Michelle E J Allerdice; Sandor E Karpathy; William L Nicholson; Michael L Levin; Travis C Smith; Tom Becker; Robert J Delph; Robert N Knight; Jana M Ritter; Jeanine H Sanders; Jerome Goddard
Journal:  Appl Environ Microbiol       Date:  2017-04-17       Impact factor: 4.792

2.  Phylogenetic Evidence for the Existence of Multiple Strains of Rickettsia parkeri in the New World.

Authors:  Fernanda A Nieri-Bastos; Arlei Marcili; Rita De Sousa; Christopher D Paddock; Marcelo B Labruna
Journal:  Appl Environ Microbiol       Date:  2018-04-02       Impact factor: 4.792

3.  Rickettsia parkeri infections diagnosed by eschar biopsy, Virginia, USA.

Authors:  Pamela Kelman; Chelsea Wright Thompson; Wayne Hynes; Christian Bergman; Cameron Lenahan; Joel S Brenner; Michelle G Brenner; Benjamin Goodman; Demetria Borges; Michael Filak; Holly Gaff
Journal:  Infection       Date:  2018-01-31       Impact factor: 3.553

4.  Phylogenetic Differentiation of Rickettsia parkeri Reveals Broad Dispersal and Distinct Clustering within North American Strains.

Authors:  Michelle E J Allerdice; Christopher D Paddock; Joy A Hecht; Jerome Goddard; Sandor E Karpathy
Journal:  Microbiol Spectr       Date:  2021-10-13

Review 5.  Rickettsia-Host-Tick Interactions: Knowledge Advances and Gaps.

Authors:  Hwan Keun Kim
Journal:  Infect Immun       Date:  2022-08-22       Impact factor: 3.609

Review 6.  Suspected and Confirmed Vector-Borne Rickettsioses of North America Associated with Human Diseases.

Authors:  Melissa Hardstone Yoshimizu; Sarah A Billeter
Journal:  Trop Med Infect Dis       Date:  2018-01-03

7.  Contribution of classical complement activation and IgM to the control of Rickettsia infection.

Authors:  Mustapha Dahmani; Jack H Cook; Jinyi C Zhu; Sean P Riley
Journal:  Mol Microbiol       Date:  2021-11-13       Impact factor: 3.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.